Breaking News
Program
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wesana Health Hldgs Inc (OP: WSNAF )

0.0045 -0.0024 (-34.78%)
Streaming Delayed Price Updated: 9:30 AM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 500
Open 0.0069
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0069
Today's Range 0.0045 - 0.0045
52wk Range 0.0028 - 0.0390
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic... 
Via Benzinga
Wesana Shareholders Vote For Psilocybin And CBD Therapy Asset Sales To Lucy Scientific
Psychedelics drug developer Wesana Health Holdings Inc. (OTCQB: WSNAF) announced all matters discussed at the company’s annual general and special shareholders meeting of June 9 were approved by a... 
Via Benzinga

Performance

YTD
-15.09%
-15.09%
1 Month
-10.00%
-10.00%
3 Month
-73.37%
-73.37%
6 Month
-44.44%
-44.44%
1 Year
-85.00%
-85.00%

More News

Read More
Disney, Amgen, First Republic, Psychedelics: How One CEO's Universal Deal-Making Approach Shapes Industries
Via Benzinga
EXCLUSIVE: Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth'
Via Benzinga
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
Via Benzinga
High-Profile Highs: How Celebrity Advocacy Is Transforming Society's Views On Psychedelics And Cannabis
Via Benzinga
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Via Benzinga
Lucy Scientific Shares Trading Higher On Asset Purchase Agreement Of Psychedelic Assets From Wesana Health
Via Benzinga
NGOs Raise Money To Help Stem Opioid Addiction With Psychedelics Program
Via Benzinga
Wesana Sells Clinic Management Services Organization To Strengthen Assets
Via Benzinga
4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed
Via Benzinga
Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved
Via Benzinga
Missed The Benzinga Psychedelics Capital Conference? Check Out Full Recording And Exclusive Coverage
Via Benzinga
Daniel Carcillo Explains How Wesana Health Is Using Psychedelics To Treat Traumatic Brain Injury
Via Benzinga
EXCLUSIVE: Catalysts To Watch For In The Psychedelic Space
Via Benzinga
Wesana Health One Step Closer To Clinical Trials Of Psilocybin And CBD Based Treatment Of Brain Injury Related MDD
Via Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
Via Benzinga
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
Via Benzinga
The Legacy Of Dr. Aaron Beck, Father Of Cognitive Therapy, Lives On In Psychedelic Medicine
Via Benzinga
Topics Death
Exposures Death
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Via Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Via Benzinga
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial
Via Benzinga
Can MDMA Treat Traumatic Brain Injury? $1.5 Million Are Being Committed To Finding Out
Via Benzinga
Psyched: Atai Launches 'Salvia Divinorum' Subsidiary, Mindset, Psilera and Wesana's Preclinical Trials, Origin Raises $5M
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.